{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Progressive disease (PD): \\>=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): \\>=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.","groups":[{"description":"Docetaxel will be given first at 40 mg/m2 IV on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1. Immediately afterwards, Bortezomib will be given at 1.6 mg/m2 IV on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.","id":"OG000","title":"Bortezomib; Docetaxel"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"7.55 months (average duration, on study to off study)","title":"Patient Response to Treatment","type":"PRIMARY","unitOfMeasure":"participants"}